Loading…
Employees: 224
Size Alumis (ALMS) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $805M, the 2389th largest of 3,117 United States companies the cockpit tracks. Shares closed at $21.81 on 6 Nov 2026.
Performance Over six months the shares fell 26.6%, against -8.0% for the median peer and -1.1% for the United States market (cap-weighted) — 5th lowest of 20 in its peer set.
Growth Revenue fell 63.1% over the last twelve months (peer median +3.5%); the operating margin is -5,479.6% (peer median 10.1%).
Valuation It trades at 45.8× enterprise value to sales against a peer median of 2.9× (2nd most expensive of 19).
Short interest Short interest is 8.6% of the free float (15 Oct 2026).
Next results Next results expected around 12 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $7.40M | $24.1M | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | $3.87M | $20.6M | -$3.15M | -$1.28M | -$250,000 |
| EBITDA | -$402M | -$424M | -$298M | -$157M | -$114M |
| Net income | -$439M | -$243M | -$294M | -$155M | -$112M |
| Free cash flow | -$352M | -$370M | -$257M | -$134M | -$110M |
| Capital expenditure | $401,000 | $653,000 | $1.73M | $4.50M | $2.41M |
| Total debt | $36.4M | $36.9M | $30.7M | $32.6M | $1.78M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ALMS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -22.8% | -3.6% | lowest of 20 |
| 6-month return | -26.6% | -8.0% | 5th lowest of 20 |
| Distance from 52-week high | -30.4% | -32.1% | 9th highest of 20 |
| Revenue growth (TTM) | -63.1% | +3.5% | lowest of 19 |
| Operating margin | -5,479.6% | 10.1% | lowest of 19 |
| EV / Sales | 45.8× | 2.9× | 2nd most expensive of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Alumis ALMS | United States | $805M | -27% | -63% | -5,480% | 45.8× | n/a | n/a |
| Guizhou Xinbang Pharmaceutical 002390.SZ | China | $805M | -10% | -13% | 4% | 0.9× | -3.0% | -0.8% |
| SK Discovery 006120.KS | South Korea | $804M | +11% | +20% | 3% | 0.8× | n/a | n/a |
| Chongqing Pharscin Pharmaceutical 002907.SZ | China | $808M | -7% | +8% | 10% | 5.7× | 10.7% | -1.4% |
| Zhejiang Anglikang Pharmaceutical 002940.SZ | China | $801M | -19% | -6% | 10% | 4.2× | 18.2% | +2.1% |
| Knight Therapeutics GUD.TO | Canada | $800M | +37% | +42% | 5% | 1.9× | 9.5% | +17.7% |
| Sanofi India SANOFI.NS | India | $800M | -3% | -6% | 26% | 4.2× | 16.5% | -8.7% |
| Annexon ANNX | United States | $796M | -26% | n/a | n/a | n/a | n/a | n/a |
| Suven Life Sciences SUVEN.NS | India | $792M | +20% | +17% | -4,228% | 849.2× | n/a | n/a |
| Lexicon Pharmaceuticals LXRX | United States | $792M | -11% | -29% | -131% | 15.9× | n/a | n/a |
| Katakura Industries 3001.T | Japan | $791M | +46% | 0% | 16% | 2.5× | 0.2% | +0.5% |
| Hunan Jiudian Pharmaceutical 300705.SZ | China | $789M | -18% | -5% | 13% | 1.9× | -1.1% | +26.1% |
| Collegium Pharmaceutical COLL | United States | $788M | -36% | +14% | 20% | 2.3× | -7.0% | +20.3% |
| Zhuzhou Qianjin Pharmaceutical 600479.SS | China | $787M | -3% | +4% | 11% | 1.4× | -1.4% | 0.0% |
| Jinghua Pharmaceutical 002349.SZ | China | $825M | -8% | +2% | 20% | 3.2× | -1.8% | +2.6% |
| CARsgen Therapeutics 2171.HK | Hong Kong | $825M | -54% | +68% | -170% | 32.3× | n/a | n/a |
| Zhejiang Int'l 000411.SZ | China | $828M | -8% | +3% | 3% | 0.3× | n/a | n/a |
| Bambusa Therapeutics BBTX | United States | $783M | n/a | n/a | n/a | n/a | n/a | n/a |
| Jiangsu Jibeier Pharmaceutical 688566.SS | China | $777M | -8% | +9% | 24% | 4.3× | 11.5% | +11.3% |
| Sanofi Consumer Healthcare India SANOFICONR.NS | India | $835M | -28% | +23% | 36% | 8.1× | 17.1% | +22.7% |
| Youcare Pharmaceutical 688658.SS | China | $776M | -41% | -7% | -13% | 2.0× | n/a | n/a |